Primary biliary cirrhosis: safety and benefits of established and emerging therapies

Bibliography

• Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013;8:303–30
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50(1):291–308
   PubMed Web of Science ®Google Scholar
• Poupon RE, Chretien Y, Chazouilleres O, et al. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004;40(2):489–94
   PubMed Web of Science ®Google Scholar
• Untas A, Boujut E, Corpechot C, et al. Quality of life and illness perception in primary biliary cirrhosis: a controlled cross-sectional study. Clin Res Hepatol Gastroenterol 2015;39(1):52–8
   PubMed Web of Science ®Google Scholar
• Beuers U, Boberg KM, Chapman RW, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237–67
   PubMed Web of Science ®Google Scholar
• Gross CR, Malinchoc M, Kim WR, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999;29(2):356–64
   PubMed Web of Science ®Google Scholar
• Aberg F, Hockerstedt K, Roine RP, et al. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant 2012;26(5):729–35
   PubMed Web of Science ®Google Scholar
• Tabibian JH MA, Masyuk TV, LaRusso NF. Cholangiocyte Physiology. Compr Physiol 2013;3:541–65
   PubMed Web of Science ®Google Scholar
• Dyson JK, Hirschfield GM, Adams DH, et al. Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2015;12(3):147–58
   PubMed Web of Science ®Google Scholar
• Maillette de Buy Wenniger LJ, Oude Elferink RP, Beuers U. Molecular targets for the treatment of fibrosing cholangiopathies. Clin Pharmacol Ther 2012;92(3):381–7
   PubMed Web of Science ®Google Scholar
• Banales JM, Saez E, Uriz M, et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56(2):687–97
   PubMed Web of Science ®Google Scholar
• Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999;29(4):1007–12
   PubMed Web of Science ®Google Scholar
• Lamireau T, Zoltowska M, Levy E, et al. Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. Life Sci 2003;72(12):1401–11
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ikeda H, Haga H, et al. Frequent cellular senescence in small bile ducts in primary biliary cirrhosis: a possible role in bile duct loss. J Pathol 2005;205(4):451–9
   PubMed Web of Science ®Google Scholar
• O’Hara SP, Tabibian JH, Splinter PL, Larusso NF. The dynamic biliary epithelia: Molecules, pathways, and disease. J Hepatol 2013;58(3):575–82
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Lindor KD. Editorial: Betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease. Aliment Pharmacol Ther 2005;41(5):490. 10.1111/apt.13068
   Web of Science ®Google Scholar
• Hohenester S, de Buy Wenniger LM, Paulusma CC, et al. A biliary HCO(3) (-) umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012;55(1):173–83
   PubMed Web of Science ®Google Scholar
• Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012;36(Suppl 1):S3–12
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ikeda H, Yamaguchi J, et al. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology 2008;48(1):186–95
   PubMed Web of Science ®Google Scholar
• Tabibian JH, O’Hara SP, Splinter PL, et al. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014;59(6):2263–75
   PubMed Web of Science ®Google Scholar
• Keitel V, Reich M, Haussinger D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol 2015;48(2-3):218–25
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148(4):751–61
   PubMed Web of Science ®Google Scholar
• Coppe JP, Patil CK, Rodier F, et al. A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS ONE 2010;5(2):e9188
   Google Scholar
• Tchkonia T, Zhu Y, van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013;123(3):966–72
   PubMed Web of Science ®Google Scholar
• Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3(6):318–28
   PubMedGoogle Scholar
• Beuers U, Hohenester S, de Buy Wenniger LJ, et al. The biliary HCO(3) (-) umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010;52(4):1489–96
   PubMed Web of Science ®Google Scholar
• Sinakos E, Marschall HU, Kowdley KV, et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 2010;52(1):197–203
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45(17):3569–72
   PubMed Web of Science ®Google Scholar
• Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81(5):687–93
   PubMed Web of Science ®Google Scholar
• Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 2015;3(1):5
   PubMed Web of Science ®Google Scholar
• Cohen JC, Cali JJ, Jelinek DF, et al. Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11-q12. Genomics 1992;14(1):153–61
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284(5418):1362–5
   PubMed Web of Science ®Google Scholar
• Li YT, Swales KE, Thomas GJ, et al. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 2007;27(12):2606–11
   PubMed Web of Science ®Google Scholar
• Hofmann AF, Zakko SF, Lira M, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005;42(6):1391–8
   PubMed Web of Science ®Google Scholar
• Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123(4):1238–51
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Macura SI, O’Hara SP, et al. Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Lab Invest 2013;93(6):733–43
   PubMed Web of Science ®Google Scholar
• Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013;58(6):1201–8
   PubMed Web of Science ®Google Scholar
• Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009;175(6):2392–405
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Fiorotto R, Fickert P, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009;49(6):1972–81
   PubMed Web of Science ®Google Scholar
• Fausther M, Dranoff JA. New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice. J Hepatol 2011;55(4):939–40
   PubMed Web of Science ®Google Scholar
• Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother 2014;15(3):365–72
   PubMed Web of Science ®Google Scholar
• Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003;38(1):196–202
   PubMed Web of Science ®Google Scholar
• Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117(4):918–25
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41(4):747–52
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;31(2):318–23
   PubMed Web of Science ®Google Scholar
• Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011;33(2):235–42
   PubMed Web of Science ®Google Scholar
• Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 2008;38(6):557–64
   PubMed Web of Science ®Google Scholar
• Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015;110:423–31
   PubMed Web of Science ®Google Scholar
• Tanaka A, Hirohara J, Nakanuma Y, et al. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol 2015;50(6):675–82
   PubMed Web of Science ®Google Scholar
• Nakano S, Nagasawa T, Ijiro T, et al. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol Res 2008;38(10):1026–39
   PubMed Web of Science ®Google Scholar
• Popov Y, Patsenker E, Stickel F, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008;48(3):453–64
   PubMed Web of Science ®Google Scholar
• Patsenker E, Popov Y, Stickel F, et al. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008;135(2):660–70
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16(9):1009–17
   PubMed Web of Science ®Google Scholar
• Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012;55(2):512–21
   PubMed Web of Science ®Google Scholar
• Wang L, Han Q, Chen H, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev 2014;23(20):2482–9
   PubMed Web of Science ®Google Scholar
• Goldblatt J, Taylor PJ, Lipman T, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122(5):1235–41
   PubMed Web of Science ®Google Scholar
• Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2010;7(6):313–19
   PubMed Web of Science ®Google Scholar
• Pells G, Mells GF, Carbone M, et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol 2013;59(1):67–73
   PubMed Web of Science ®Google Scholar
• Hollingsworth KG, Newton JL, Robinson L, et al. Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis. J Hepatol 2010;53(1):155–61
   PubMed Web of Science ®Google Scholar
• Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30(1):325–32
   PubMed Web of Science ®Google Scholar
• Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006;44:180–1
   Web of Science ®Google Scholar